My contribution to a board
I could help a board examine whether management's technology account describes an operating capability or only the completion of a project. In a manufacturer, that difference may concern the continued interpretation of records, an unresolved supplier dependency or the people needed to assess a change. I would bring experience of making those distinctions explicit, including the cost of preserving a capability after a replacement has begun operating. I would not present myself as a substitute for a quality director, manufacturing specialist or legal adviser.
My board exposure has been as Orvanel's CIO, presenting since January 2020. I have not served as a director. The move into a seat would change my responsibility from making an executive recommendation to joining a collective judgement about the enterprise. I would need to listen across the board's wider agenda and assess management's explanation without taking over its technical work. That is the contribution I am preparing to make, with a clear recognition that experience in presenting to directors is different from experience of being one.
Judgement in practice
01Questioning what a completion result establishes
The restoration exercises taught me to separate evidence of a backup job from evidence that a reviewer could interpret the restored package. For a board, the useful question is not how an engineer should configure the recovery environment. It is whether the management claim is supported by the kind of test being presented, and whether the limits are disclosed. I would ask which important uses have been examined, who assessed the result and what remains outside the scope. I would also consider whether the proposed response is proportionate. A finding should lead to a reasoned choice of further work, rather than either a premature closure or an unlimited programme justified by an imprecise concern.
02Recognising the obligation left after a modernisation
The archive reader decision exposed a continuing dependency that the proposed saving assumed had ended. I could bring that question to oversight of a wider investment: what must the enterprise still operate after the project has delivered its intended replacement? I would expect management to identify the cost, ownership and evidence needed for eventual retirement. I would not demand that every older capability disappear on a planned date, nor accept indefinite retention without review. Directors should be able to understand why the obligation remains and challenge the route chosen to meet it. My experience would help make that discussion practical while leaving technical design and quality acceptance with the appropriate executives.
03Testing whether a portfolio has credible review capacity
I recommended deferring an analytics proposal because the specialist participation it required was unavailable alongside the approved programme. At board level, I would examine whether a portfolio relies repeatedly on the same people or on expertise that has not yet been developed. A fully funded plan can still contain unsupported capacity assumptions. The question is not whether management has enough names on a project chart, but whether the required decisions can be prepared and assessed while continuing responsibilities are met. I would also ask about the cost of delay and credible alternatives. Challenging an execution assumption should not prevent the board from recognising the potential value of the underlying proposal.
My first year on a board
My initial work would be to understand how the company makes and preserves its most consequential operating explanations. I would read investment papers and the subsequent accounts of a few completed programmes, then discuss the differences with management through the chair's agreed process. Site visits and conversations with manufacturing and quality leaders would help me understand the context behind the technology reports. I would avoid treating my employer's arrangements as a model the new company should automatically adopt.
I would learn the board's risk priorities, financial position and decision calendar before recommending changes to its information. In particular, I would look at how ongoing obligations appear after a programme closes, how supplier dependencies are assessed and how exceptions reach the right forum. I would discuss with fellow directors where my experience adds value and where another specialist should lead. Formal induction and continuing development in governance and finance would be necessary parts of the year. I would measure a useful contribution by whether the board can ask clearer questions and understand management's answers, rather than by the number of technical interventions attributed to me.
Conflicts and their management
Orvanel's commercial and supplier relationships create possible conflicts that a short biography cannot resolve. Before accepting a role I would disclose relevant connections and examine whether access to information or participation in a decision could put my responsibilities in tension. That examination must consider the actual company and proposed work, including relationships that may develop during the appointment. I would obtain employer consent and appropriate professional advice where needed. A general statement of independence would be premature.
My proposed capacity is twenty-one days per year for an external contribution, including ordinary preparation and meetings. Committee demands, site visits, induction and exceptional events would need discussion before the commitment is agreed. I have no current directorships. I also make no IICA Databank registration claim; any proposed Indian appointment would need its own assessment of requirements and eligibility. My willingness to contribute cannot replace that process. I would decline a role if its commercial context or demands prevented me from performing it with the attention the enterprise requires.
My independence statement
My employment, supplier contacts and commercial relationships would require formal examination for the specific appointment; the absence of a current seat does not establish independence.
Board and committee exposure
Presented to the Board or a committee
Orvanel Therapeutics
Board technology investment and risk discussions
January 2020–present
CIO presenting programme evidence and continuing dependencies; no director or committee membership.
Committee contribution
Chair and member readiness| Capacity | Committees |
|---|
| Ready to join | Technology committee · Risk committee with complementary manufacturing and financial expertise |
|---|
Capacity and preferences
- Time available
- 21 days per year
- Current directorships
- 0
- Sectors
- Established manufacturing enterprises · Laboratory and industrial service businesses outside present conflicts · Companies renewing technology with substantial historical record obligations
- Company type
- A European private or mid-sized listed company with a defined technology oversight need
- Company stage
- Renewal of established operations rather than an unproven clinical development proposition
The seat I am pursuing
A technology committee contribution in an established manufacturing or laboratory-services enterprise is the closest fit to my experience. A risk committee role could also be relevant alongside colleagues with complementary financial, sector and governance depth. I would not currently seek to chair an audit committee or present myself as a clinical development specialist. I want an appointment where a careful question about record continuity, supplier dependence or review capacity can improve collective judgement. The mandate should be clear enough that management retains responsibility for execution and directors can evaluate its account without becoming an informal project team.
Governance learning and readiness
IICA Independent Directors’ Databank: Not yet registered
No IICA Databank registration is claimed. A proposed Indian appointment would require separate assessment of its applicable requirements and my eligibility.
- Director duties and collective judgement in the proposed jurisdiction
- Financial reporting and capital oversight beyond a CIO budget
- Appointment-specific conflicts, independence and sector responsibilities